mRNA therapeutics Market Outlook 2026–2036: Growth Drivers, Key Companies, Strategic Developments & Adoption Forecast — A Meticulous Next™ Foresight Brief

This Meticulous Next™ brief examines mRNA therapeutics outside infectious disease vaccines, meaning mRNA used to replace missing proteins in rare disease and to engineer cells inside the body, such as in vivo CAR-T. It tests how fast late stage rare disease programmes and in vivo cell engineering deals turn into approved products and revenue, and which participants capture value among developers, large pharmaceutical companies and suppliers.

Pharmaceutical acquirers have moved first on in vivo cell engineering. AbbVie announced the acquisition of Capstan Therapeutics on 30 June 2025 for up to USD 2.1 billion, and its lead programme CPTX2309 is a targeted lipid nanoparticle that delivers anti-CD19 CAR mRNA to T cells in vivo for B-cell mediated autoimmune disease, now in a phase I study in healthy volunteers. A trade report of April 2026 counted in vivo CAR-T deals of more than USD 15 billion in about 12 months, including Eli Lilly with Kelonia at USD 7 billion, AstraZeneca with EsoBiotec at USD 1 billion and Gilead Sciences with Interius at USD 350 million. The conclusion is that large buyers have priced in vivo cell engineering as a core modality before any programme has reached approval, so the next two years of clinical data decide whether the prices hold.

Protein replacement is the more advanced use. In January 2026 Moderna agreed with Recordati that Recordati takes global commercialisation of mRNA-3927 for propionic acidemia, with USD 50 million upfront and up to USD 110 million in near term development and regulatory milestones, plus commercial milestones and tiered royalties. The registrational study has reached target enrolment, with pivotal data expected in 2026. The conclusion is that a first mRNA protein replacement therapy is close to a regulatory decision, and its outcome sets the template for rare disease programmes that follow.

Delivery decides which applications scale. Two mRNAs encode the two enzyme subunits in mRNA-3927, and Capstan delivers CAR mRNA selectively to CD8+ T cells outside the liver, while competing in vivo approaches use lentiviral vectors and circular RNA. The conclusion is that lipid nanoparticles able to reach cells beyond the liver, and to be dosed more than once, are the scarce capability in this market.

The brief treats mRNA therapeutics as an accelerating signal with a ten year horizon to 2036. It identifies which applications, regions and operators scale first and what each means for developers, large pharmaceutical companies and suppliers. It is a focused 104-page decision brief that presents an indicative trajectory rather than a segmented market model.

mRNA therapeutics are medicines in which messenger RNA, usually carried in a lipid nanoparticle, instructs the cells of the patient to make a protein, a receptor or an editing enzyme.

Protein replacement supplies an enzyme or protein missing in a rare genetic disease, and in vivo engineering delivers instructions to cells inside the body so that cells are modified without being removed.

Targeting chemistry, lipid design and redosing schedules define performance.

Uses are rare metabolic disease, autoimmune disease, cancer and delivery of gene editing components.

The limits are early stage clinical data, delivery outside the liver, durability of effect and the safety of lipid carriers. The period turns on whether pivotal protein replacement data and first in vivo cell engineering data confirm the deal prices.

The mRNA therapeutics market, covering mRNA based protein replacement, in vivo cell engineering and gene editing delivery products and development revenue outside infectious disease vaccines, is valued at USD 1.0–2.0 billion in 2026 and is projected to reach USD 13.79–27.58 billion by 2036, at a CAGR of 30%.

The 2026 base rests on licensing and development revenue, collaboration payments and early product sales outside vaccines. Growth then follows first protein replacement approvals, in vivo cell engineering data and wider rare disease and autoimmune indications.

The forecast is sensitive to pivotal trial results, delivery beyond the liver and lipid supply. Regionally, North America leads on deals and trials, Europe on commercial partnering, and Asia-Pacific on manufacturing and early clinical programmes.

The base case assumes pivotal protein replacement data support a first approval by 2028 and in vivo CAR-T programmes reach late stage trials by 2030, giving the inflection in 2031. An accelerated case assumes early approvals and strong autoimmune data, bringing the inflection to 2029 and lifting the 2036 value to the top of the range. A delayed case assumes safety signals or weak durability in in vivo programmes, holding growth at the bottom of the range.

Growth drivers

• Pharma acquisitions of in vivo platforms.
• Registrational rare disease programmes.
• Targeted lipid nanoparticles reaching cells outside the liver.
• Autoimmune and oncology uses of in vivo CAR-T.

Enablers

• Platform manufacturing built for vaccines.
• Licensing and commercial partnerships.
• Lipid and raw material suppliers.
• Academic research on delivery.

Restraints and barriers

• Early stage clinical data.
• Delivery to cells outside the liver.
• Competition from lentiviral in vivo approaches.
• Immunogenicity and safety of lipid carriers.

The direction of mRNA therapeutics is set by the need for off-the-shelf alternatives to cell therapy and enzyme replacement, regulatory pathways for rare disease and platform products, delivery chemistry and lipid design, pharma acquisitions and partnering, and manufacturing cost and lipid supply.

The key participants in mRNA therapeutics include Moderna, Inc., BioNTech SE, Arcturus Therapeutics Holdings Inc., AbbVie Inc., Eli Lilly and Company, AstraZeneca PLC, Gilead Sciences, Inc., Recordati S.p.A., Sanofi, Pfizer Inc., GSK plc, Intellia Therapeutics, Inc., Beam Therapeutics Inc., Sail Biomedicines, Inc., Orna Therapeutics, Inc., Umoja Biopharma, Inc., Acuitas Therapeutics Inc., Evonik Industries AG, Lonza Group Ltd, Thermo Fisher Scientific Inc., Bristol-Myers Squibb Company, Novartis AG, Merck KGaA, Danaher Corporation, National Institutes of Health, Broad Institute, University of Pennsylvania, Wellcome Trust, Gates Foundation, Biomedical Advanced Research and Development Authority, U.S. Food and Drug Administration, European Medicines Agency, Medicines and Healthcare products Regulatory Agency, Pharmaceuticals and Medical Devices Agency, National Medical Products Administration, Biotechnology Innovation Organization, Pharmaceutical Research and Manufacturers of America, American Society of Gene and Cell Therapy, Alliance for Regenerative Medicine and European Federation of Pharmaceutical Industries and Associations.

The brief profiles representative participants in each archetype and assesses which are positioned to lead as mRNA therapeutics mature.

Moderna and Arcturus lead among mRNA developers with rare disease programmes, AbbVie, Eli Lilly, AstraZeneca and Gilead Sciences lead among acquirers of in vivo platforms, and Acuitas, Evonik and Lonza lead among suppliers of lipids and manufacturing. Competitive intensity is moderate in 2026 and rises as first clinical data arrive.

Where value migrates.

In 2026 value sits with developers holding late stage rare disease programmes and with owners of in vivo platforms, because deal payments and licences are the revenue available. By 2031 it moves toward owners of approved protein replacement and early in vivo products, because repeat dosing creates recurring sales. By 2036 it settles in targeted delivery platforms that work across many tissues. Margins hold for developers with proprietary lipids and narrow for those that rely on licensed carriers.

The signals converge on capital ahead of clinical proof. In vivo CAR-T deals above USD 15 billion in about 12 months and a licence with USD 50 million upfront support growth, while early stage data, delivery outside the liver and competition from lentiviral approaches limit the pace.

Structural limits show where progress could slow: early stage clinical data, delivery to cells outside the liver, competition from lentiviral in vivo approaches, and safety of lipid carriers. The brief therefore tracks four indicators: pivotal trial results, first in vivo CAR-T clinical data, approvals, and deal value.

Rare metabolic disease first, then autoimmune disease, then oncology and gene editing delivery are the expected order of adoption.